Guohai Shi
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 13
- Cancer, Lipids, and Metabolism 12
- Molecular Biology top 2%
- Renal and related cancers 24
- Epigenetics and DNA Methylation 12
-
- Renal cell carcinoma treatment 49
- Ferroptosis and cancer prognosis 29
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 12
- Immunology top 10%
-
- Bladder and Urothelial Cancer Treatments 11
- Journals
- Nature Communications (1 paper)SHILAP Revista de lepidopterología (3 papers)PLoS ONE (1 paper)
- Partner nations
- ChinaUnited StatesAustria
In The Last Decade
Guohai Shi
100 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Cancer Research 2.5k
- Molecular Biology 3.0k
- Pulmonary and Respiratory Medicine 879
- Oncology 490
- Immunology 265
Countries citing papers authored by Guohai Shi
This map shows the geographic impact of Guohai Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guohai Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guohai Shi more than expected).
Fields of papers citing papers by Guohai Shi
This network shows the impact of papers produced by Guohai Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guohai Shi. The network helps show where Guohai Shi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Guohai Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2023 | 56 | |
| 3 | 2023 | 8 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 21 | |
| 6 | 2022 | 3 | |
| 7 | 2021 | 11 | |
| 8 | 2021 | 18 | |
| 9 | 2021 | 17 | |
| 10 | Review of Research on the Role of Irisin in Tumors | 2020 | 1 |
| 11 | 2020 | 40 | |
| 12 | 2019 | 16 | |
| 13 | 2018 | 46 | |
| 14 | 2017 | 25 | |
| 15 | 2016 | 59 | |
| 16 | 2016 | 27 | |
| 17 | Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAsbreakdown → | 2016 | 1644 |
| 18 | 2014 | 1 | |
| 19 | 2013 | 5 | |
| 20 | 2011 | 1 |
About Guohai Shi
Guohai Shi is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 101 papers that have together received 3.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (49 papers), Ferroptosis and cancer prognosis (29 papers), Renal and related cancers (24 papers), Cancer Genomics and Diagnostics (13 papers), Epigenetics and DNA Methylation (12 papers), Cancer, Lipids, and Metabolism (12 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Bladder and Urothelial Cancer Treatments (11 papers). The work is most often cited by research in Cancer Research (2.5k citations), Molecular Biology (3.0k citations) and Pulmonary and Respiratory Medicine (879 citations). Guohai Shi has collaborated with scholars based in China, United States and Austria. Frequent co-authors include Qiupeng Zheng, Xianghuo He, Weijie Guo, Chunyang Bao, Shenglin Huang, Jie Chen, Dongbin Lyu, Bing Chen, Yanting Luo and Yan Li. Their work appears in journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.